Evercore ISI analyst John Scott told investors that the unit could potentially bring in even more than $14 billion. He pointed to the fact that when Merck ($MRK) sold its consumer health unit in 2014, it put it on the block at $10 billion. But the unit drew a lot of interest, and Bayer ended up paying more than $14 billion for it. Scott said the Reuters report points to Pfizer's continued "willingness to engage in corporate restructuring transactions," even though its earlier inversion attempt and deal to merge with Allergan didn't work out.